Valuation: Cesca Therapeutics Inc

Market Cap 11.09K 9.86K 9.14K 8.32K 15.69K 1.05M 15.94K 110K 43.07K 549K 41.63K 40.75K 1.75M P/E 2022
-0.16x
P/E 2023 -0.08x
Enterprise Value 9.29M 8.26M 7.66M 6.97M 13.15M 882M 13.36M 92.03M 36.08M 460M 34.88M 34.13M 1.47B EV / Sales 2022
0.97x
EV / Sales 2023 1.18x
Free-Float
100%
Yield 2022 *
-
Yield 2023 -
Manager TitleAgeSince
Chief Executive Officer 55 03/11/2016
Investor Relations Contact - -
Director TitleAgeSince
Chairman 55 03/11/2016
Director/Board Member - 14/07/2023
Change 5-day change 1-year change 3-year change Capi.($)
-4.15%-9.96% - - 1.58K
-1.02%+4.66%+20.23%+55.21% 32.51B
+0.96%+2.32%+9.33%+31.00% 25.91B
+2.59%+1.55%+12.13%+15.64% 8.04B
+2.97%+4.57%+85.25%+100.50% 7.53B
+2.78%+4.96%+36.33%+43.41% 6.48B
+1.26%+4.62%+36.45%+108.76% 5.25B
-2.58%+2.64%+65.21%-13.73% 3.61B
-0.35%-12.44%+70.16%+154.75% 2.95B
-1.69%-5.20%-2.33%+59.22% 2.75B
Average +0.08%+1.33%+36.97%+61.64% 10.56B
Weighted average by Cap. +0.47%+3.79%+26.32%+51.59%

Financials

2022 2023
Net sales 10.48M 9.32M 8.64M 7.86M 14.83M 995M 15.07M 104M 40.7M 519M 39.34M 38.51M 1.66B 9.44M 8.4M 7.78M 7.08M 13.36M 896M 13.57M 93.54M 36.67M 468M 35.45M 34.69M 1.49B
Net income -11.27M -10.02M -9.29M -8.45M -15.94M -1.07B -16.2M -112M -43.76M -558M -42.3M -41.4M -1.78B -17.98M -15.98M -14.81M -13.47M -25.43M -1.71B -25.83M -178M -69.8M -890M -67.46M -66.02M -2.84B
Net Debt 6.89M 6.12M 5.67M 5.16M 9.74M 654M 9.9M 68.21M 26.75M 341M 25.85M 25.3M 1.09B 9.28M 8.25M 7.65M 6.96M 13.13M 881M 13.34M 91.92M 36.04M 460M 34.84M 34.09M 1.47B
Logo Cesca Therapeutics Inc
ThermoGenesis Holdings, Inc. develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. The Company provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, the PXP platform for point-of-care cell-based therapies and X-Series products for cell processing services. Its product lines include Clinical Bio-Banking Applications, Point-of-Care Applications and Cell Processing. Its Clinical Bio-Banking Applications include AXP II Automated Cell Separation System and BioArchive Automated Cryopreservation System. Its Point-of-Care Applications include PXP Point-of-Care System, and PXP-1000 System. Its Cell Processing includes X-Series Products for general laboratory use: X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The Company markets and sells its medical device products through independent distributors.
Employees
-